share_log

PainReform | 6-K: Report of foreign private issuer (related to financial reporting)

PainReform | 6-K: Report of foreign private issuer (related to financial reporting)

PainReform | 6-K：外国发行人报告（业绩相关）
美股SEC公告 ·  2024/08/16 04:47

Moomoo AI 已提取核心信息

PainReform Ltd. reported financial results for H1 2024, highlighting progress in its Phase 3 clinical trial for PRF-110, a post-operative pain relief drug. The company has enrolled over 200 patients across 8 U.S. sites, with preliminary top-line results expected in Q3 2024.Financial results show a net loss of $12.8 million, up from $4.5 million in H1 2023, primarily due to increased R&D expenses for the Phase 3 trial. Research and development costs rose to $11.4 million from $2.7 million year-over-year. As of June 30, 2024, PainReform had $2.8 million in cash and cash equivalents.The company faces substantial doubt about its ability to continue as a going concern, with funding expected to last only through Q4 2024. Management plans to seek additional capital through equity sales or strategic partnerships to sustain operations and complete clinical trials. Despite financial challenges, PainReform remains focused on advancing PRF-110 through clinical development.
PainReform Ltd. reported financial results for H1 2024, highlighting progress in its Phase 3 clinical trial for PRF-110, a post-operative pain relief drug. The company has enrolled over 200 patients across 8 U.S. sites, with preliminary top-line results expected in Q3 2024.Financial results show a net loss of $12.8 million, up from $4.5 million in H1 2023, primarily due to increased R&D expenses for the Phase 3 trial. Research and development costs rose to $11.4 million from $2.7 million year-over-year. As of June 30, 2024, PainReform had $2.8 million in cash and cash equivalents.The company faces substantial doubt about its ability to continue as a going concern, with funding expected to last only through Q4 2024. Management plans to seek additional capital through equity sales or strategic partnerships to sustain operations and complete clinical trials. Despite financial challenges, PainReform remains focused on advancing PRF-110 through clinical development.
PainReform有限公司公布了2024年上半年的财务结果，强调其PRF-110的第三阶段临床试验取得进展，这是一种用于术后的疼痛缓解药物。该公司在美国的8个地点招募了超过200名患者，预计将在2024年第三季度发布初步的顶线结果。财务结果显示净亏损为1280万美元，高于2023年上半年的450万美元，这主要由于第三阶段试验的研发费用增加。研究和开发成本从270万美元上升至1140万美元，同比大幅增加。截止至2024年6月30日，PainReform的现金及现金等价物为280万美元。该公司面临持续经营能力的重大疑虑，资金预计只能维持到2024年第四季度。管理层计划通过股权融资或战略合作伙伴关系来寻求额外资本，以维持运营并完成临床试验。尽管面临财务挑战，PainReform仍然专注于推动PRF-110的临床开发。
PainReform有限公司公布了2024年上半年的财务结果，强调其PRF-110的第三阶段临床试验取得进展，这是一种用于术后的疼痛缓解药物。该公司在美国的8个地点招募了超过200名患者，预计将在2024年第三季度发布初步的顶线结果。财务结果显示净亏损为1280万美元，高于2023年上半年的450万美元，这主要由于第三阶段试验的研发费用增加。研究和开发成本从270万美元上升至1140万美元，同比大幅增加。截止至2024年6月30日，PainReform的现金及现金等价物为280万美元。该公司面临持续经营能力的重大疑虑，资金预计只能维持到2024年第四季度。管理层计划通过股权融资或战略合作伙伴关系来寻求额外资本，以维持运营并完成临床试验。尽管面临财务挑战，PainReform仍然专注于推动PRF-110的临床开发。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间